Sawyers, C. Targeted cancer therapy. Nature 432, 294–297 (2004).

Article  CAS  PubMed  Google Scholar 

Chabner, B. A. & Roberts, T. G. Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65–72 (2005).

Article  CAS  PubMed  Google Scholar 

Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal. Transduct. Target. Ther. 6, 201 (2021).

Article  PubMed Central  PubMed  Google Scholar 

Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).

Article  CAS  PubMed  Google Scholar 

Hochhaus, A. et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N. Engl. J. Med. 376, 917–927 (2017).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).

Article  CAS  PubMed  Google Scholar 

Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735–742 (2011).

Article  CAS  PubMed  Google Scholar 

Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).

Article  CAS  PubMed  Google Scholar 

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Jänne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120–131 (2022).

Article  PubMed  Google Scholar 

Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371–2381 (2021).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Chang, L., Ruiz, P., Ito, T. & Sellers, W. R. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell 39, 466–479 (2021).

Article  CAS  PubMed Central  PubMed  Google Scholar 

AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).

Article  Google Scholar 

Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).

Article  CAS  PubMed  Google Scholar 

The Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).

Article  Google Scholar 

Hsiehchen, D. & Hsieh, A. Nearing saturation of cancer driver gene discovery. J. Hum. Genet. 63, 941–943 (2018).

Article  CAS  PubMed  Google Scholar 

Lucchesi, J. C. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 59, 37–44 (1968).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches into the discovery of anticancer drugs. Science 278, 1064–1068 (1997).

Article  CAS  PubMed  Google Scholar 

Simon, J. A. et al. Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. Cancer Res. 60, 328–333 (2000).

CAS  PubMed  Google Scholar 

Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

Article  CAS  PubMed  Google Scholar 

McDonald, E. R. 3rd et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592 (2017).

Article  CAS  PubMed  Google Scholar 

Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature 568, 511–516 (2019).

Article  CAS  PubMed  Google Scholar 

Hage Chehade, C. et al. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J. Clin. https://doi.org/10.3322/caac.21870 (2025).

Article  PubMed Central  PubMed  Google Scholar 

Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 564–576 (2018).

Article  CAS  PubMed  Google Scholar 

Engstrom, L. D. et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13, 2412–2431 (2023).

Article  CAS  PubMed Central  PubMed  Google Scholar 

O’Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer. Nat. Rev. Genet. 18, 613–623 (2017).

Article  PubMed  Google Scholar 

Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug. Discov. 19, 23–38 (2020).

Article  CAS  PubMed  Google Scholar 

Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321–337 (2018).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Mina, M. et al. Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies. Cancer Cell 32, 155–168 (2017).

Article  CAS  PubMed  Google Scholar 

Kim, Y.-A., Cho, D.-Y., Dao, P. & Przytycka, T. M. MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types. Bioinformatics 31, i284–i292 (2015).

Article  CAS  PubMed Central  PubMed  Google Scholar 

Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q. & Varmus, H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife 4, e06907 (2015).

Article  PubMed Central